Abstracts tagged "belimumab"

Abstract Number: 149 • 2015 ACR/ARHP Annual Meeting
Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014
Deanna Hill¹, Hong Kan², Peter Egger³, David J. Chang⁴, Amanda Eudy^1,5, Joe Maskell³ and Karen H. Costenbader⁶, ¹Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ²Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, ³Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, United Kingdom, ⁴US Medical Affairs, GlaxoSmithKline, Philadelphia, PA, ⁵Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, a B-lymphocyte stimulator, was FDA-approved March 2011 for the treatment of adult patients with active, autoantibody-positive SLE receiving standard of care (SOC) medications.…
Abstract Number: 729 • 2015 ACR/ARHP Annual Meeting
The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Cosmin Dascalu¹, Anne Davidson², Meggan C. Mackay³, Richard Furie⁴, Weiqing Huang⁵ and Cynthia Aranow⁶, ¹Medicine/Rheumatology, North Shore- Long Island Jewish, Manhasset, NY, ²Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ³Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…
Abstract Number: 732 • 2015 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study
Ioannis Parodis¹, Christopher Sjöwall², Andreas Jönsen³, Agneta Zickert¹, Martina Frodlund², Daniel Ramsköld¹, Anders A. Bengtsson³ and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Belimumab is the first biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated through 2 phase III…
Abstract Number: 741 • 2015 ACR/ARHP Annual Meeting
Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients
Katie Pascoe¹, Steve Lobosco², David Bell³, Ben Hoskin³, Sulabha Ramachandran⁴, Bonnie Pobiner⁵ and David Chang⁶, ¹Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom, ²Adelphi Real World Ltd., Macclesfield, United Kingdom, ³Autoimmune, Adelphi Real World Ltd., Manchester, United Kingdom, ⁴Value Evidence and Outcomes, GlaxoSmithKline, Renaissance Centre, PA, ⁵Immuno-Inflammation Therapy Area, GlaxoSmithKline, Triangle Park, NC, ⁶US Medical Affairs, GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Patient and physician treatment satisfaction influences long-term adherence with a treatment regimen. The primary objective was to identify factors linked to satisfaction with the…
Abstract Number: 1616 • 2014 ACR/ARHP Annual Meeting
Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease-Associated Dysfunctional Signaling
Rachael Hawtin¹, Wouter Korver², Erik Evensen², Diane Longo², Drew Hotson², Nikil Wale², Andy Conroy², Alessandra Cesano², Barbara Mittleman², Shirley Tu², Matt Westfall², Tsung Lin³, Vik Rao⁴, Elena Peeva⁵, Stephen Benoit⁵, Martin Hodge³, James D. Clark³, Jean-Baptiste Telliez³ and Aaron R. Winkler⁴, ¹Nodality Inc., South San Francisco, CA, ²Nodality, Inc., South San Francisco, CA, ³Immunoscience, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁴Inflammation and Remodeling, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁵Precision Medicine, Pfizer Biotherapeutics Research and Development, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-system rheumatic disease with widely differing clinical manifestations and outcomes. Treatment is generally immunosuppressive, with no available…
Abstract Number: 672 • 2014 ACR/ARHP Annual Meeting
Favorable Response to Belimumab in Pediatric-Onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Jennifer Taylor², Xiao Qing Li³, Liza Mariel Bermudez¹, Josephine Isgro¹, Andrew H. Eichenfield⁴, Amy J. Starr⁴, Lisa F. Imundo⁵, Jill P. Buyon⁶, Richard Furie⁷, Diane L. Kamen⁸, Susan Manzi⁹, Michelle Petri¹⁰, Rosalind Ramsey-Goldman¹¹, Ronald van Vollenhoven¹², Daniel J. Wallace¹³ and Anca Askanase⁴, ¹Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ²Pediatrics, Columbia University Medical Center, New York, NY, ³Adult Rheumatology, Columbia University Medical Center, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, ⁶Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁷Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁸Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹⁰Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, ¹²Karolinska Institute, Stockholm, Sweden, ¹³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-lymphocyte stimulator. It was approved by the FDA in 2011 for treatment of active,…
Abstract Number: 670 • 2014 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Elisabet Svenungsson¹, Magnus Axelsson² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²AlbaNova, Stockholm University, Stockholm, Sweden
Background/Purpose B cells have a central role in Systemic Lupus Erythematosus (SLE) and autoantibody production. B-Lymphocyte Stimulator (BLyS) is important for the activation and maintenance…
Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Josefina Cortes¹, Carlos Marras², Jose Luis Andreu³, Jaime Calvo-Alen⁴, Angel M. Garcia-Aparicio⁵, Elvira Diez Alvarez⁶, Carlos Coronell⁷, Elena Morejon⁷, Alessandra Perna⁸, Volker Koscielny⁸ and Josep Ordi-Ros¹, ¹Internal Medicine, Vall d´Hebron Hospital, Barcelona, Spain, ²Rheumatology, Virgen de la Arrixaca Hospital, Murcia, Spain, ³Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ⁶Rheumatology, Leon Hospital, Leon, Spain, ⁷Medical Department, GlaxoSmithKline, Madrid, Spain, ⁸Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…
Abstract Number: 511 • 2013 ACR/ARHP Annual Meeting
Salivary Gland Lymphocyte Pattern Associated With Response To Belimumab In Primary sjogren’ssyndrome: Results Of The Beliss Study
Raphaèle Seror¹, Thierry Lazure², Frederic Desmoulins³, Stephan Pavy⁴, Corinne Miceli-Richard⁵, Gabriel Baron⁶, Philippe Ravaud⁷ and Xavier Mariette⁸, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Pathology, INSERM U1012 - Université Paris XI, Le Kremlin Bicêtre, France, ³Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁴Rheumatology, Hopital Bicetre, Paris, France, ⁵Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ⁶Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁸Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: To address the change in labial salivary gland (LSG) inflammation after Belimumab (biological treatment inhibiting soluble BAFF/BLyS) therapy in pSS patients and identify predictor…
Abstract Number: 2617 • 2012 ACR/ARHP Annual Meeting
Outcomes Associated with Belimumab in Black/African American Patients with Systemic Lupus Erythematous in Clinical Practice Settings in the United States
Christopher E. Collins¹, Siva Narayanan², Maria Dall'era³, Greg Dennis⁴, Alan Oglesby⁵, Mark B. McGuire⁶, Ramesh Pappu⁷, Charles T. Molta⁸ and Greg Keenan⁴, ¹Rheumatology, Washington Hospital Ctr, Washington, DC, ²Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Human Genome Sciences, Inc., Rockville, MD, ⁵GlaxoSmithKline, Research Triangle Park, NC, ⁶Medical Data Analytics, Parsippany, NJ, ⁷GlaxoSmithKline, USA, Philadelphia, PA, ⁸GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Effectiveness of belimumab in black/African American (AA) patients (pts) with Systemic Lupus Erythematous (SLE) is yet to be adequately demonstrated. The objective of this…
Abstract Number: 2241 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Baseline Disease Activity
Ann E. Clarke¹, Susan Manzi², Michelle Petri³, Richard Furie⁴, Ronald F. van Vollenhoven⁵, Simon Cooper⁶, Z. John Zhong⁶, William W. Freimuth⁶ and Arthur Weinstein⁷, ¹Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴North Shore-LIJ Health System, Lake Success, NY, ⁵Karolinska University Hospital, Stockholm, Sweden, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Washington Hospital Center, Washington, DC
Background/Purpose: To assess the efficacy of belimumab in patients with SLE who had high disease activity at baseline, as defined by SELENA-SLEDAI score ≥10. Methods: In…
Abstract Number: 1417 • 2012 ACR/ARHP Annual Meeting
Favorable Response to Belimumab At Three Months
Katrina M. Shum¹, Jill P. Buyon², H. Michael Belmont¹, Andrew G. Franks Jr.³, Richard Furie⁴, Diane L. Kamen⁵, Susan Manzi⁶, Michelle Petri⁷, Rosalind Ramsey-Goldman⁸, Chung-E Tseng¹, Ronald F. van Vollenhoven⁹, Daniel Wallace¹⁰ and Anca Askanase¹, ¹NYU School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Dermatology & Medicine (Rheumatology), New York University, New York, NY, ⁴North Shore-LIJ Health System, Lake Success, NY, ⁵Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹The Karolinska Institute, Stockholm, Sweden, ¹⁰Cedars-Sinai/UCLA, Los Angeles, CA
Background/Purpose: Belimumab (Benlysta) is a monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the use…
Abstract Number: 615 • 2012 ACR/ARHP Annual Meeting
Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials Are Predictive of Severe Flare At 52 Weeks
Michelle Petri¹, Ronald F. van Vollenhoven², Roger A. Levy³, Sandra V. Navarra⁴, Ricard Cervera⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Jill P. Buyon⁷, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Karolinska University Hospital, Stockholm, Sweden, ³Medicine, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Hospital Clinic, Barcelona, Spain, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Identification and validation of potential serologic biomarkers of clinically meaningful SLE flare are major unmet medical needs in clinical practice and trials. The purpose…
Abstract Number: 616 • 2012 ACR/ARHP Annual Meeting
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Wendy Cai¹, Cecil Chen¹, Z. John Zhong¹, William W. Freimuth¹, William Lewis² and David Subich³, ¹Human Genome Sciences, Inc., Rockville, MD, ²Covance Clinical Research Unit, Inc., Dallas, TX, ³Covance Clinical Research Unit, Inc., Daytona Beach, FL
Background/Purpose: Belimumab is a recombinant, human Ig-G1λ monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein, a member of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].